April 14 – 19, 2023, AACR

1) Generation of Profound Anti-Tumor Immunity by AUR-109, A Spectrum-Selective Tyrosine Kinase Inhibitor, Either as a Single Agent or in Combination with Immune Checkpoint Inhibitors
2) A Highly Differentiated A2AR Inhibitor for Potential Use in Cancer Therapy